Krystal Biotech Inc (KRYS) Receives Consensus Rating of “Buy” from Analysts
Krystal Biotech Inc (NASDAQ:KRYS) has been assigned a consensus rating of “Buy” from the six analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $33.67.
A number of brokerages have recently weighed in on KRYS. Chardan Capital restated a “buy” rating and issued a $35.00 price objective on shares of Krystal Biotech in a research note on Monday, August 6th. LADENBURG THALM/SH SH set a $38.00 target price on shares of Krystal Biotech and gave the stock a “buy” rating in a research report on Thursday, July 19th. Zacks Investment Research lowered shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, September 1st. William Blair began coverage on shares of Krystal Biotech in a research report on Tuesday, July 10th. They set an “outperform” rating on the stock. Finally, Cantor Fitzgerald began coverage on shares of Krystal Biotech in a research report on Monday, September 10th. They set an “overweight” rating and a $28.00 target price on the stock.
Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC increased its position in Krystal Biotech by 552.2% during the second quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock worth $182,000 after acquiring an additional 10,331 shares during the period. BlackRock Inc. increased its position in Krystal Biotech by 75.4% during the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after acquiring an additional 5,607 shares during the period. Finally, Millennium Management LLC bought a new position in Krystal Biotech during the fourth quarter worth $266,000. 23.07% of the stock is currently owned by institutional investors and hedge funds.
Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 6th. The company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.12. equities research analysts anticipate that Krystal Biotech will post -1.03 EPS for the current year.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Read More: What is a Tariff?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.